{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.87","value":"50.5"},{"groupId":"OG001","spread":"17.54","value":"47.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Blood samples were collected at indicated time points to analyze the t1/2 of niraparib.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Niraparib 300 mg in fasted condition","id":"OG000","title":"FE Niraparib Fasted"},{"description":"Participants received Niraparib 300 mg in fed condition","id":"OG001","title":"FE Niraparib Fed"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic population. Only those participants with data available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose","title":"Terminal Elimination Half-life (t1/2) Following Administration of Niraparib (FE Sub-study)","type":"SECONDARY","unitOfMeasure":"Hour"}